Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 189Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2010  |  Volume : 1  |  Issue : 3  |  Page : 104-105

Outcomes research and drug development

Head, Market Access & Pricing Emerging Markets Business Unit Pfizer Inc

Correspondence Address:
Sandeep Duttagupta
Head, Market Access & Pricing Emerging Markets Business Unit Pfizer Inc

Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 21814630

Rights and PermissionsRights and Permissions

With increasing health care cost, focus needs to be given towards value-for-money, especially in the context of innovative drugs. A multi-disciplinary approach towards drug development is important in order to demonstrate the value of innovation to physicians and patients. Input into the drug development process at various stages of clinical trials must incorporate patient-focused endpoints and analyses. Demonstrating value of drugs will help ensure that innovative therapies should be seen as health care investment and not expense.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded411    
    Comments [Add]    

Recommend this journal